Product
Debio 4326
1 clinical trial
1 indication
Indication
Central Precocious PubertyClinical trial
An Open-Label, Single-Arm, Multi-Center, Phase 3 Study on the Efficacy, Safety, and Pharmacokinetics of Debio 4326, a Triptorelin 12-month Formulation, in Pediatric Participants Who Are Receiving Gonadotropin-Releasing Hormone Agonist Therapy for Central Precocious PubertyStatus: Recruiting, Estimated PCD: 2026-07-01